注册
登录
全国服务热线：
18086415513
赛培新增产品文献： 人β- 内啡肽（β-EP）、心 肌营养素 -1（CT-1）及 N- 末端 B 型利钠 肽（NT-proBNP）ELISA试剂盒
发布时间：2021-10-19 18:12:22
【摘要】目的 探讨沙库巴曲缬沙坦治疗慢性心力衰竭的疗效和安全性，并观察其对 1 年生存率的影响。方法 入选 2017 年 5 月至 2019 年 4 月在我院连续住院的慢性心力衰竭患者 96 例，分成两组，对照组应用常规抗心衰治疗，研究组在常规抗心衰治疗基础上联合沙库巴曲缬 沙坦治疗。主要观察终点：治疗 3 个月时患者的临床疗效变化，次要观察终点：①治疗 3 个月时超声心动图相关指标的变化：左心射血分数 （LVEF）、左心舒张末径（LVEDD）、左房内径（LA）、舒张早期与晚期间血流最大峰值的比值（E/A）及舒张早期最大峰值（E ／ e´）； ②血清生物标志物包括血清 β- 内啡肽（β-EP）、心肌营养素 -1（CT-1）及 N- 末端 B 型利钠肽（NT-proBNP）变化；③治疗一年后比 较两组生存率的差异。结果 治疗 3 个月后，沙库巴曲缬沙坦研究组有效性明显优于对照组（95.8 % vs 83.3 %，P ＜ 0.05）；研究组的次要 观察终点 LVEF 改善程度及 E/A 水平升高幅度显著优于对照组（P ＜ 0.05），LVEDD、LA 及 E/e´ 水平降低幅度显著优于对照组（P ＜ 0.05）， 血清 β-EP 及 CT-1 水平降低幅度显著大于对照组（P ＜ 0.05），研究组的 NT-proBNP 降低幅度显著大于对照组（P ＜ 0.05）。平均随访 时间 1 年，研究组 1 年生存率显著高于对照组（83.7% vs 65.9%，P=0.03）。结论 沙库巴曲缬沙坦可明显改善慢性心力衰竭患者的近期疗效， 并且可显著提高 1 年生存率。
【关键词】慢性心力衰竭；心功能；沙库巴曲缬沙坦；β- 内啡肽；心肌营养素 -1
Efficacy and Safety of Sacubitril / Valsartan for Chronic Heart Failure JIANG Yang, DONG Peng* , LIU Fang, YAN Ping Department of Cardiology, Aviation General Hospital, Beijing 100012, China 【Abstract】Objective To investigate the efficacy, safety and influencing factors of Sacubitril / Valsartan in the treatment of chronic heart failure, and to observe its effect on 1-year survival rate. Methods 96 patients with chronic heart failure who were continuously hospitalized in our hospital from May 2017 to April 2019 were divided into two groups. The control group was treated with conventional anti-heart failure treatment. The treatment group was treated with conventional anti-heart failure + Sacubitril / Valsartan. After 3 months of treatment, the efficacy and safety were evaluated. The primary endpoint was the difference of efficacy between the two groups. The secondary endpoints were: ① Changes in echocardiography-related praameters before and after treatment: left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter ( LVEDD), left atrial inner diameter (LA), ratio of maximum peak blood flow (E / A) during early and late diastole, and maximum peak value during early diastole (E / e´); ② serum biomarkers before and after treatment including β-endorphin (β-EP), cardiac trophin-1(CT-1), and N-terminal pronatriuretic peptide (NT-proBNP); ③ the difference of survival rate between the two groups after one year treatment. Results Compared with the control group, the efficacy of the treatment group was significantly improved after 3 months treatment (95.8 % vs 83.3 %, P< 0.05). LVEF and E/A level in the treatment group was significantly improved (P< 0.05), LVEDD, LA and E/ E ´ levels was significantly decreased (P< 0.05) comparison with the control group. Also serum level of β-EP, CT-1 and NT-proBNP significantly decreased when compared with the control group (P < 0.05). After 1 year follow-up, patients in the treatment group had a significantly better survival probability than those in control group (83.7% vs 65.9%, P < 0.05). Conclusion Sacubitril / Valsartan can significantly improve the short-term efficacy and one-year survival rate of patients with chronic heart failure. 【Key Words】Chronic heart failure; Cardiac function; Sacubitril / Valsartan; β-endorphin; Cardiac trophin-1
沙库巴曲缬沙坦治疗慢性心力衰竭的有效性及安全性研究_姜阳 (1).pdf
